Literature DB >> 15129416

Effects of buspirone and alprazolam treatment on the startle-potentiated startle response.

Randall L Commissaris1, Elizabeth A Fomum, Bonita J Leavell.   

Abstract

The startle potentiated startle (SPS) paradigm has been reported to be an effective procedure for studying the conditioned enhancement of acoustic startle in the absence of electric shocks or extinction. This study examines the effects of two anxiolytic treatments, buspirone and alprazolam, on this SPS effect. Subjects were tested in the SPS paradigm 2 days a week (Monday and Thursday) for 10 weeks. Each startle test session consisted of 10 Noise Alone trials (115 dB acoustic noise burst presented for 40 ms) and 10 Light+Noise trials (115 dB acoustic stimuli presented during the latter 40 ms of a 3,540 ms period in which a 15-watt light was illuminated). Although there was no difference in startle amplitude on Noise Alone trials when compared to Light+Noise trials initially, by the end of the first test session and continuing throughout the duration of the experiment, startle amplitude on Light+Noise trials was significantly (approximately 50-75%) greater than on Noise Alone trials. After five control (i.e., no injection) SPS test sessions, once-weekly drug challenges were conducted over the course of 7 weeks. In these weekly drug challenges, subjects received acute treatment with various doses of the benzodiazepine anxiolytic alprazolam (0.25, 0.5, 1.0 mg/kg) or the novel anxiolytic buspirone (1.0, 2.0, 4.0 mg/kg); subjects also received vehicle treatment (0.5% methylcellulose) on one treatment day. All treatments were administered intraperitoneally (i.p.), 15 min before the start of startle testing. Consistent with previous reports, buspirone increased and alprazolam decreased startle amplitude on the Noise Alone trials; these effects were dose-related. Both agents reduced the magnitude of the SPS effect when it was expressed as the Light+Noise startle amplitude minus the Noise Alone startle amplitude. These findings are similar to the effects of these treatments in the traditional shock-based fear-potentiated startle paradigm. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15129416     DOI: 10.1002/da.20006

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  5 in total

1.  The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.

Authors:  Michel A Steiner; Hugues Lecourt; Francois Jenck
Journal:  Psychopharmacology (Berl)       Date:  2012-05-17       Impact factor: 4.530

2.  The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats.

Authors:  Xia Li; Katarzyna Kaczanowska; M G Finn; Athina Markou; Victoria B Risbrough
Journal:  Neuropharmacology       Date:  2015-05-19       Impact factor: 5.250

3.  The auditory startle response in post-traumatic stress disorder.

Authors:  S E Siegelaar; M Olff; L J Bour; D Veelo; A H Zwinderman; G van Bruggen; G J de Vries; S Raabe; C Cupido; J H T M Koelman; M A J Tijssen
Journal:  Exp Brain Res       Date:  2006-03-09       Impact factor: 1.972

4.  Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats.

Authors:  Cathrin Rohleder; Fabienne Jung; Hanna Mertgens; Dirk Wiedermann; Michael Sué; Bernd Neumaier; Rudolf Graf; F Markus Leweke; Heike Endepols
Journal:  Front Behav Neurosci       Date:  2014-05-22       Impact factor: 3.558

5.  Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.

Authors:  Katrina L Paumier; Stacey J Sukoff Rizzo; Zdenek Berger; Yi Chen; Cathleen Gonzales; Edward Kaftan; Li Li; Susan Lotarski; Michael Monaghan; Wei Shen; Polina Stolyar; Dmytro Vasilyev; Margaret Zaleska; Warren D Hirst; John Dunlop
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.